Padcev (enfortumab vedotin)

pCPA File Number: 21705

Negotiation Status:

Concluded with an LOI

Indication(s):

Unresectable, locally advanced or metastatic urothelial cancer in adult patients who have previously received a platinum-containing chemotherapy and programmed death receptor-1 or programmed death-ligand 1 inhibitor therapy

Sponsor/Manufacturer:

Seagen Canada Inc.

CDA-AMC Project Number:

PC0251-000

pCPA Engagement Letter Issued:

2022-06-28

Negotiation Process Concluded:

2022-11-28